Much of the recent excitement in the translational field of tumor immunology and
immunotherapy has been generated by the recognition that immune checkpoint proteins can …

Cancer immunotherapy has been established as standard of care in different tumor entities.
After the first reports on synergistic effects with radiotherapy and the induction of abscopal …

The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition
but is commensurate with significant immune-related adverse events suboptimally limiting …

We hypothesized that the combination of oncolytic virotherapy with immune checkpoint
modulators would reduce tumor burden by direct cell lysis and stimulate antitumor immunity …

We have identified desmoglein-2 (DSG-2) as the primary high-affinity receptor used by
adenoviruses Ad3, Ad7, Ad11 and Ad14. These serotypes represent key human pathogens …

Background aims Mouse models indicate that adoptive transfer of regulatory T cells (Treg)
may suppress graft-versus-host-disease (GvHD) while preserving graft-versus-leukemia …

The chemokine CXCL12 and its receptor CXCR4 are expressed widely in human cancers,
including ovarian cancer, in which they are associated with disease progression at the …

Purpose: Blockade of CTLA-4 by antibodies has potentiated antitumor T-cell responses in
both preclinical models and clinical trials. However, treatment with CTLA-4 blocking …

Triple‐negative breast cancer (TNBC) is an aggressive and immunogenic subtype of breast
cancer. This tumorigenicity is independent of hormonal or HER2 pathways because of a lack …

As cancer immunotherapy continues to benefit from novel approaches which cut immune
'brake pedals'(eg anti-PD1 and anti-CTLA4 antibodies) and push immune cell gas pedals …